Skip to content

Study · Case report or series · n = 1 · 2022

6 results

Semaglutide is effective in type 2 diabetes and obesity with schizophrenia.

Noda K, Kato T, Nomura N, Sakai M, Kubota S, Hirose T, Liu Y, Takahashi Y, Takao K, Mizuno M, Hirota T, Suwa T, Horikawa Y, Yabe D

Diabetology international15 Jun 2022Cited by 9 (Europe PMC)

PMID36117924 (opens in a new tab)PMCIDPMC9477985 (opens in a new tab)DOI10.1007/s13340-022-00590-1 (opens in a new tab)PepBankPUB-36117924
Source linkPubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanCase report or seriesEfficacy outcome

    In a woman with obesity, type 2 diabetes and schizophrenia, switching from dulaglutide to semaglutide reduced and maintained HbA1c for 6 months, more effectively than dulaglutide.

    In plain wordsIn one woman with type 2 diabetes, obesity and schizophrenia, semaglutide lowered blood sugar markers more than dulaglutide had, for 6 months.

    Peptide
    Semaglutide
    Outcome
    DecreaseHbA1c after switch from dulaglutide
    Study

    n = 1

    Comparator
    Dulaglutide
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    After discharge, semaglutide was remarkably more effective than dulaglutide in that it reduced and maintained the patient's HbA1c and body weight for 6 months after initiation of the drug.
    2 context sentences
    Summary · context
    This case was a 50-year-old obese woman having type 2 diabetes and schizophrenia.
    Summary · context
    We chose the GLP-1 receptor agonist semaglutide to replace dulaglutide along with a multidisciplinary team approach that included a cognitive-behavioral therapist.
  2. 02HumanCase report or seriesEfficacy outcome

    In a woman with obesity, type 2 diabetes and schizophrenia, switching from dulaglutide to semaglutide reduced and maintained body weight for 6 months, more effectively than dulaglutide.

    In plain wordsIn one woman with type 2 diabetes, obesity and schizophrenia, semaglutide lowered body weight more than dulaglutide had, for 6 months.

    Peptide
    Semaglutide
    Outcome
    DecreaseBody weight after switch from dulaglutide
    Study

    n = 1

    Comparator
    Dulaglutide
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    After discharge, semaglutide was remarkably more effective than dulaglutide in that it reduced and maintained the patient's HbA1c and body weight for 6 months after initiation of the drug.
    2 context sentences
    Summary · context
    This case was a 50-year-old obese woman having type 2 diabetes and schizophrenia.
    Summary · context
    We chose the GLP-1 receptor agonist semaglutide to replace dulaglutide along with a multidisciplinary team approach that included a cognitive-behavioral therapist.
  3. 03HumanCase report or seriesEfficacy outcome

    In a woman with obesity, type 2 diabetes and schizophrenia, the patient perceived her hunger as suppressed when she started semaglutide 0.5 mg.

    In plain wordsOne woman with type 2 diabetes, obesity and schizophrenia felt less hungry after starting semaglutide.

    Peptide
    Semaglutide
    Outcome
    DecreasePerceived hunger
    Study

    n = 1

    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    0.5 mgAs given in this study (human).

    Source sentences

    Summary
    The patient perceived that her hunger was suppressed when she started receiving semaglutide 0.5 mg.
    2 context sentences
    Summary · context
    This case was a 50-year-old obese woman having type 2 diabetes and schizophrenia.
    Summary · context
    We chose the GLP-1 receptor agonist semaglutide to replace dulaglutide along with a multidisciplinary team approach that included a cognitive-behavioral therapist.

Studies that did not test the peptide alone3

In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Dulaglutide (Trulicity).

  1. 04HumanNot a test of Dulaglutide (Trulicity) aloneCase report or seriesEfficacy outcome

    In a woman with diabetes and schizophrenia, HbA1c reached 10.2% despite multiple diabetes drugs including dulaglutide.

    In plain wordsIn a woman with diabetes and schizophrenia, HbA1c reached 10.2% despite multiple drugs including dulaglutide.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    IncreaseInadequate glycaemic control
    Study

    n = 1

    Outcome group
    Glycemic control · Metabolic and weight

    Measurements

    HbA1c
    10.2%
    multiple diabetes drugs including dulaglutide

    Source sentences

    Summary
    Her HbA1c was elevated to as high as 10.2% despite the use of multiple anti-diabetes drugs including the GLP-1 receptor agonist dulaglutide, and she was hospitalized in our department.
    2 context sentences
    Summary · context
    This case was a 50-year-old obese woman having type 2 diabetes and schizophrenia.
    Summary · context
    We chose the GLP-1 receptor agonist semaglutide to replace dulaglutide along with a multidisciplinary team approach that included a cognitive-behavioral therapist.

    In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).

  2. 05HumanNot a test of Dulaglutide (Trulicity) aloneCase report or seriesEfficacy outcome

    In a woman with diabetes and schizophrenia, the dulaglutide regimen controlled HbA1c less effectively than subsequent semaglutide with multidisciplinary care.

    In plain wordsIn a woman with diabetes and schizophrenia, the dulaglutide regimen controlled blood sugar less effectively than subsequent semaglutide with multidisciplinary care.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    IncreaseHbA1c control after treatment switch
    Study

    n = 1

    Comparator
    Semaglutide with multidisciplinary care
    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    After discharge, semaglutide was remarkably more effective than dulaglutide in that it reduced and maintained the patient's HbA1c and body weight for 6 months after initiation of the drug.
    2 context sentences
    Summary · context
    This case was a 50-year-old obese woman having type 2 diabetes and schizophrenia.
    Summary · context
    We chose the GLP-1 receptor agonist semaglutide to replace dulaglutide along with a multidisciplinary team approach that included a cognitive-behavioral therapist.

    In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).

  3. 06HumanNot a test of Dulaglutide (Trulicity) aloneCase report or seriesEfficacy outcome

    In a woman with diabetes and schizophrenia, the dulaglutide regimen controlled weight less effectively than subsequent semaglutide with multidisciplinary care.

    In plain wordsIn a woman with diabetes and schizophrenia, the dulaglutide regimen controlled weight less effectively than subsequent semaglutide with multidisciplinary care.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    Direction not reportedBody weight control after treatment switch
    Study

    n = 1

    Comparator
    Semaglutide with multidisciplinary care
    Outcome group
    Body weight · Metabolic and weight

    Source sentences

    Summary
    After discharge, semaglutide was remarkably more effective than dulaglutide in that it reduced and maintained the patient's HbA1c and body weight for 6 months after initiation of the drug.
    2 context sentences
    Summary · context
    This case was a 50-year-old obese woman having type 2 diabetes and schizophrenia.
    Summary · context
    We chose the GLP-1 receptor agonist semaglutide to replace dulaglutide along with a multidisciplinary team approach that included a cognitive-behavioral therapist.

    In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Versions 4 to 9Current

    28 Oct 2026, 02:03 UTC

    The same notice was added 6 times, first on 22 Oct 2026, 02:26 UTC. The status did not change between them.

    Study results updated

  2. Version 3

    21 Oct 2026, 18:59 UTC

    Study data updated · source update from Europe PMC

  3. Version 2

    11 Oct 2026, 00:50 UTC

    Study results updated

  4. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.